Lorbrena was analyzed in a clinical trial of 296 patients with ALK+ NSCLC whose cancer had migrated to multiple parts of the body including the brain. A trial comparing lorlatinib with crizotinib was conducted, with a primary endpoint of "progression-free survival", which is the period of time a patient is in remission (the tumor ceases growth). Preclinical studies are investigating lorlatinib for treatment of neuroblastoma. In 2017, Pfizer announced that lorlatinib was shown to have activity against lung and brain tumors in people with ALK or ROS1 positive advanced non-small-cell lung cancer. Approval
In 2015, FDA granted Pfizer orphan drug status for lorlatinib for the treatment of NSCLC. In 2018, the FDA approved lortalinib for second- or third-line treatment of ALK-positive metastatic NSCLC. In February 2019, the European CHMP of EMA recommended the granting of a conditional marketing authorisation. In May 2019 the European Commission approved lorlatinib for the 28 countries of the EU, also as a second- or third-line treatment. References
External links
"Lorlatinib". Drug Information Portal. U.S. National Library of Medicine.
Lathosterolosis is a defect in cholesterol biosynthesis. See also
SC5DL
Lathosterol

References


== External links ==